- Home
- GVH vs MYNZ Comparison
GVH vs MYNZ Comparison
Compare GVH & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GVH
- MYNZ
- Stock Information
- Founded
- GVH 2016
- MYNZ 2021
- Country
- GVH Australia
- MYNZ Germany
- Employees
- GVH N/A
- MYNZ N/A
- Industry
- GVH
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- GVH
- MYNZ Health Care
- Exchange
- GVH Nasdaq
- MYNZ Nasdaq
- Market Cap
- GVH 7.4M
- MYNZ 7.0M
- IPO Year
- GVH 2023
- MYNZ 2021
- Fundamental
- Price
- GVH $1.38
- MYNZ $2.44
- Analyst Decision
- GVH
- MYNZ Buy
- Analyst Count
- GVH 0
- MYNZ 2
- Target Price
- GVH N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- GVH 1.5M
- MYNZ 310.7K
- Earning Date
- GVH 02-12-2025
- MYNZ 05-27-2025
- Dividend Yield
- GVH N/A
- MYNZ N/A
- EPS Growth
- GVH 12.04
- MYNZ N/A
- EPS
- GVH 0.09
- MYNZ N/A
- Revenue
- GVH $16,540,178.00
- MYNZ $893,991.00
- Revenue This Year
- GVH N/A
- MYNZ $42.95
- Revenue Next Year
- GVH N/A
- MYNZ N/A
- P/E Ratio
- GVH $15.44
- MYNZ N/A
- Revenue Growth
- GVH N/A
- MYNZ N/A
- 52 Week Low
- GVH $0.47
- MYNZ $0.18
- 52 Week High
- GVH $2.57
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- GVH 83.42
- MYNZ 37.09
- Support Level
- GVH $1.32
- MYNZ $2.18
- Resistance Level
- GVH $1.56
- MYNZ $2.57
- Average True Range (ATR)
- GVH 0.21
- MYNZ 0.31
- MACD
- GVH 0.09
- MYNZ -0.01
- Stochastic Oscillator
- GVH 83.02
- MYNZ 12.04
About GVH Globavend Holdings Limited
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.